Evolus (EOLS) Scheduled to Post Quarterly Earnings on Tuesday

Evolus (NASDAQ:EOLS) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). The business had revenue of $61.00 million during the quarter, compared to analysts’ expectations of $61.14 million. On average, analysts expect Evolus to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolus Price Performance

Evolus stock opened at $13.30 on Friday. The stock’s fifty day moving average price is $13.31 and its two-hundred day moving average price is $11.42. Evolus has a one year low of $7.07 and a one year high of $15.43. The firm has a market cap of $832.45 million, a PE ratio of -12.20 and a beta of 1.47.

Insider Buying and Selling at Evolus

In related news, insider David Moatazedi sold 7,706 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $13.08, for a total transaction of $100,794.48. Following the sale, the insider now owns 792,416 shares of the company’s stock, valued at approximately $10,364,801.28. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, insider Rui Avelar sold 27,603 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $384,233.76. Following the sale, the insider now owns 372,288 shares of the company’s stock, valued at approximately $5,182,248.96. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Moatazedi sold 7,706 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $13.08, for a total value of $100,794.48. Following the sale, the insider now directly owns 792,416 shares in the company, valued at approximately $10,364,801.28. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,038 shares of company stock valued at $674,232. 5.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

EOLS has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Friday, March 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a report on Wednesday, April 10th. Finally, Barclays raised Evolus from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $10.00 to $16.00 in a report on Monday, January 29th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.